secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0000950170-23-040954
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TScan Q2 net loss $24M, cash $208.8M; heme and solid tumor trials advancing
---------------------------------------------------------------------------

- Net loss of $24.0M in Q2 2023, vs $15.1M in Q2 2022; revenue $3.1M (down from $4.1M).
- Ended Q2 2023 with cash $208.8M; raising $134.7M net from June public offering; funded into 2026.
- FDA cleared IND for TSC-200-A0201 (HPV16); third solid tumor IND; three TCR-Ts to enter Phase 1 basket study H2 2023.
- Heme malignancies: TSC-100/101 at dose level 2, no DLTs; expect RP2D and interim data by end of 2023.
- Plans to file INDs for three more TCR-Ts by year-end, including PRAME-targeting TSC-203-A0201.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000095017023040954/0000950170-23-040954-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000095017023040954/tcrx-20230810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-040954

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer